Artikel
Health-economic evaluation of MetroMapping – decision analysis within the EU HORIZON EUROPE project 4DPICTURE
Suche in Medline nach
Autoren
-
Lára Rún Hallsson
- UMIT TIROL, Department of Public Health, Health Services Research, and Health Technology Assessment, Österreich
-
Petra Mösl
- UMIT TIROL, Department of Public Health, Health Services Research, and Health Technology Assessment, Österreich
-
Judith Rietjens
- Erasmus University Medical Center, Department of Public Health, Niederlande; TU Delft, Department of Industrial Design, Delft, Niederlande
-
Ida Korfage
- Erasmus University Medical Center, Department of Public Health, Niederlande
-
Karina Dahl Steffensen
- University of Southern Denmark, Institute of Regional Health Research, Dänemark; Lillebaelt University Hospital of Southern Denmark, Center for Shared Decision Making, Dänemark
-
Ewout Steyerberg
- Leiden University, Leiden University Medical Center, Leiden, Niederlande
-
Anne Stiggelbout
- Leiden University, Leiden University Medical Center, Leiden, Niederlande
-
Uwe Siebert
- UMIT TIROL, Department of Public Health, Health Services Research, and Health Technology Assessment, Österreich; Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Departments of Epidemiology and Health Policy & Management, USA
-
Gaby Sroczynski
- UMIT TIROL, Department of Public Health, Health Services Research, and Health Technology Assessment, Österreich
| Veröffentlicht: | 21. März 2023 |
|---|
Gliederung
Text
Background/research question: Patients with cancer often have to make complex decisions about treatment, with the options varying in risk profiles and effects on survival and quality of life. The service design methodology MetroMapping facilitates the redesign and optimization of patient’s care paths. However, MetroMapping is lacking the integration of data-driven decision-support tools (DSTs). Further, the integration of DSTs into MetroMapping has not yet been evaluated.
Objectives: The EU Horizon Europe project 4D PICTURE (Design-based Data-Driven Decision-support Tools: Producing Improved Cancer Outcomes Through User-Centred Research), aims to further develop MetroMapping, to redesign care paths that include novel DSTs. Within this project we aim to empirically evaluate the application of MetroMapping (including a variation of DSTs) regarding short- and long-term costs and effects as well as cost-effectiveness.
Methods: First we will conduct a short-term cost-effectiveness along the MetroMapping evaluation study. Second, we will develop and validate a long-term decision-analytic model simulating the application of MetroMapping vs. no MetroMapping. The model will be populated with data-driven results of prediction models, derived country specific inpatient and outpatient costs, derived EQ-5D scores for utilities as well as data from the published literature and national databases. We will apply the decision-analytic model to the context of three countries (Denmark, Spain, Netherlands) to evaluate long term benefits, costs and cost-effectiveness of MetroMapping compared to no MetroMapping, in the case of melanoma. Sensitivity analyses will be performed to assess the costs and cost-effectiveness of different versions of MetroMapping, with variants of DSTs embedded. The decision model will be validated on three levels (face-validity, internal and external validation).
Expected Results: Our results will provide patient-relevant health outcomes (e.g., remaining life expectancy, quality-adjusted remaining life years (QALY)), costs, incremental cost-effectiveness ratios (ICER), and benefit-harm and cost-effectiveness tradeoff planes of MetroMapping with and without different DSTs embedded in order to inform guideline developers and health policy decision makers.
Competing interests: This work is funded by the European Commission Horizon Europe Grant 4D PICTURE (GA-101057332).
